Eva Kontseková

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

Petr Novák, Reinhold Schmidt, Eva Kontseková et al. · The Lancet Neurology · 2016 · 298 citations

Vaccination, Alzheimer's Disease, Vaccine Development +9

Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo

Norbert Žilka, Peter Filipčík, Peter Koson et al. · FEBS Letters · 2006 · 246 citations

Sporadic Alzheimer, Molecular Biology, Neurochemical Biomarkers +19

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Eva Kontseková, Norbert Žilka, Branislav Kováčech et al. · Alzheimer s Research & Therapy · 2014 · 243 citations · Full text

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Petr Novák, Branislav Kováčech, Stanislav Katina et al. · Nature Aging · 2021 · 168 citations

Neurodegenerative Diseases, Alzheimer's Disease, Active Immunotherapy +9

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Petr Novák, Reinhold Schmidt, Eva Kontseková et al. · Alzheimer s Research & Therapy · 2018 · 140 citations · Full text